Researchers at National Jewish Health have published data that will help medical providers better understand the susceptibility of various nontuberculous mycobacteria (NTM) to different drugs. This new antibiogram will assist providers in making informed treatment decisions for patients with NTM. An antibiogram is a summary of antimicrobial susceptibility rates for bacterial pathogens, which provides comprehensive information about antimicrobial resistance. The research paper was published in the journal *Diagnostic Microbiology and Infectious Disease* and is the result of a collaboration between the researchers at National Jewish Health Advanced Diagnostic Laboratories and infectious disease physicians at National Jewish Health.

“The prevalence of NTM has been increasing in the United States and it is important to track the antibiotic susceptibility of these organisms,” said Reeti Khare, PhD, D(ABMM), director of the Infectious Disease Laboratory and senior author of the study. “Our unique position as a national diagnostic lab provides us access to the thousands of NTM isolates required to detect these patterns of susceptibility.”

NTM are a group of bacteria naturally found in soil, water and dust worldwide. Everyone inhales NTM into their lungs as part of daily life, and in most people the organisms do no harm. But in a small number of vulnerable individuals, NTM causes lung
In this study, researchers performed drug susceptibility testing for 14 rapidly growing mycobacteria, using the largest sample size to date. Their results showed that rapidly growing NTM organisms were typically susceptible to amikacin (82% to 100% of isolates) and showed high to moderate susceptibility for clofazimine and tigecycline and variable patterns for the remaining drugs. Complete speciation/sub speciation also uncovered different patterns of susceptibility between highly similar organisms.

“Rapidly growing mycobacteria are an uncommon but increasingly are a cause of disease, and their management is typically complex,” said Charles Daley, MD, chief of the Division of Mycobacterial and Respiratory Infections at National Jewish Health and co-author on the study. “The research results can help guide therapy and influence antibiotic selection, especially when guidelines are lacking for rare mycobacteria.”

**National Jewish Health** is the leading respiratory hospital in the nation. Founded 125 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of children and adults with respiratory, cardiac, immune and related disorders. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit the [media resources](#) page.

**Media Resources**

We have many faculty members, from bench scientists to clinicians, who can speak on almost any aspect of respiratory, immune, cardiac and gastrointestinal disease as well as lung cancer and basic immunology.

- [Accomplishments & Awards](#)
- [Annual Report](#)
- [Financials](#)

**Media Contacts**

Our team is available to arrange interviews, discuss events and story ideas.

**Adam Dormuth**

303.398.1002 office  
970.222.5034 mobile  
dormutha@njhealth.org

**Jessica Berry**

303.398.1082 office  
303.807.9491 mobile  
berryj@njhealth.org